Enliven Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Aug 13, 2025 and accepted by EDGAR at Aug 13, 2025, 16:17 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2025-04-01 to 2025-06-30 | $21.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-01-01 to 2025-06-30 | $46.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$28.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-30 | −$60.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-04-01 to 2025-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2025-01-01 to 2025-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-04-01 to 2025-06-30 | −$25.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | −$53.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | −$0.49 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-30 | −$1.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | −$0.49 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-01-01 to 2025-06-30 | −$1.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 52,105,052 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 51,083,841 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | −$41.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2025-01-01 to 2025-06-30 | $159.0k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2025-06-30 | $119.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $495.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $503.9m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $15.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $15.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-30 | $488.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-25-179845. Last ingested by Listed: Nov 5, 2026, 17:49 ET. Listed shows no prices and gives no investment advice.